Yixin Wang

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi request reprint Gene expression profiles and prognostic markers for primary breast cancer
    Yixin Wang
    Veridex LLC, Johnson and Johnson Company, San Diego, CA, USA
    Methods Mol Biol 377:131-8. 2007
  2. ncbi request reprint Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
    Yixin Wang
    Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Clin Oncol 22:1564-71. 2004
  3. ncbi request reprint Gene expression-driven diagnostics and pharmacogenomics in cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    Curr Opin Mol Ther 7:246-50. 2005
  4. doi request reprint Copy number alterations that predict metastatic capability of human breast cancer
    Yi Zhang
    Veridex LLC, a Johnson and Johnson Company, San Diego, California, USA
    Cancer Res 69:3795-801. 2009
  5. pmc Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer
    Yuqiu Jiang
    Veridex LLC, a Johnson and Johnson Company, 33 Technology Drive, Warren, NJ 07059, USA
    J Mol Diagn 10:346-54. 2008
  6. ncbi request reprint Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia
    Mitch Raponi
    Veridex, L L C a Johnson and Johnson Company, San Diego, California 92121, USA
    Clin Cancer Res 13:2254-60. 2007
  7. pmc A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin
    Dimitri Talantov
    Veridex LLC, 33 Technology Dr, Warren, NJ 07059, USA
    J Mol Diagn 8:320-9. 2006
  8. pmc Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative
    Dondapati Chowdary
    Veridex LLC, Johnson and Johnson Company, Warren, NJ, USA
    J Mol Diagn 8:31-9. 2006
  9. pmc Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
    Jack X Yu
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    BMC Cancer 7:182. 2007
  10. ncbi request reprint Novel genes associated with malignant melanoma but not benign melanocytic lesions
    Dmitri Talantov
    Veridex, LLC, a Johnson and Johnson Company, San Diego, California 92121, USA
    Clin Cancer Res 11:7234-42. 2005

Detail Information

Publications32

  1. ncbi request reprint Gene expression profiles and prognostic markers for primary breast cancer
    Yixin Wang
    Veridex LLC, Johnson and Johnson Company, San Diego, CA, USA
    Methods Mol Biol 377:131-8. 2007
    ....
  2. ncbi request reprint Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
    Yixin Wang
    Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Clin Oncol 22:1564-71. 2004
    ..In this study, we used DNA chip technology to systematically identify new prognostic markers for tumor relapse in Dukes' B patients...
  3. ncbi request reprint Gene expression-driven diagnostics and pharmacogenomics in cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    Curr Opin Mol Ther 7:246-50. 2005
    ..Studies on gene expression profiling of clinically relevant tissue samples with the aim of finding gene markers to support disease prognosis and therapy decisions are reviewed...
  4. doi request reprint Copy number alterations that predict metastatic capability of human breast cancer
    Yi Zhang
    Veridex LLC, a Johnson and Johnson Company, San Diego, California, USA
    Cancer Res 69:3795-801. 2009
    ....
  5. pmc Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer
    Yuqiu Jiang
    Veridex LLC, a Johnson and Johnson Company, 33 Technology Drive, Warren, NJ 07059, USA
    J Mol Diagn 10:346-54. 2008
    ..The ability to identify colon cancer patients with an unfavorable outcome may help patients at high risk for recurrence to seek more aggressive therapy...
  6. ncbi request reprint Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia
    Mitch Raponi
    Veridex, L L C a Johnson and Johnson Company, San Diego, California 92121, USA
    Clin Cancer Res 13:2254-60. 2007
    ..Microarray technology was used to identify gene expression markers that predict response to the orally available farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in acute myelogenous leukemia (AML)...
  7. pmc A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin
    Dimitri Talantov
    Veridex LLC, 33 Technology Dr, Warren, NJ 07059, USA
    J Mol Diagn 8:320-9. 2006
    ..Lastly, our assay demonstrated an accuracy of 76% when tested on an independent set of 48 metastatic samples, 37 of which were either a known primary or initially presented as carcinoma of unknown primary but were subsequently resolved...
  8. pmc Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative
    Dondapati Chowdary
    Veridex LLC, Johnson and Johnson Company, Warren, NJ, USA
    J Mol Diagn 8:31-9. 2006
    ..This novel finding demonstrates that prognostic signatures can be obtained from RNAlater preservative-suspended tissues, an important step in bringing gene expression signatures to the clinic...
  9. pmc Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
    Jack X Yu
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    BMC Cancer 7:182. 2007
    ..Published prognostic gene signatures in breast cancer have few genes in common. Here we provide a rationale for this observation by studying the prognostic power and the underlying biological pathways of different gene signatures...
  10. ncbi request reprint Novel genes associated with malignant melanoma but not benign melanocytic lesions
    Dmitri Talantov
    Veridex, LLC, a Johnson and Johnson Company, San Diego, California 92121, USA
    Clin Cancer Res 11:7234-42. 2005
    ..The identification of melanoma-specific deregulated genes could provide molecular markers for lymph node staging assays and further insight into melanoma tumorigenesis...
  11. ncbi request reprint A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
    Blood 111:2589-96. 2008
    ..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...
  12. pmc Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis
    John Backus
    Veridex, LLC, P O Box 4920, 33 Technology Drive, Warren, NJ 07059, USA
    J Mol Diagn 7:327-36. 2005
    ..An intraoperative molecular assay using these markers has the potential to significantly reduce second surgeries for patients undergoing SLN dissection...
  13. ncbi request reprint Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung
    Mitch Raponi
    Molecular Diagnostics, Veridex LLC a Johnson and Johnson Company, 3210 Merryfriend Row, San Diego, CA 92121, USA
    Cancer Res 66:7466-72. 2006
    ..0002; HR, 3.54; 95% CI, 1.74-7.19). This prognostic signature could be used to identify patients with early-stage high-risk NSCLC who might benefit from adjuvant therapy following surgery...
  14. doi request reprint The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy
    Yi Zhang
    Veridex LLC, Johnson and Johnson Company, San Diego, CA, USA
    Breast Cancer Res Treat 116:303-9. 2009
    ..To assess the benefit from adjuvant systemic tamoxifen therapy in breast cancer risk groups identified by the previously established prognostic 76-gene signature...
  15. pmc Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays
    Marina Bibikova
    Genetic Analysis, Illumina, Inc, 9885 Towne Center Drive, San Diego, CA 92121, USA
    Am J Pathol 165:1799-807. 2004
    ..The DASL assay system should prove useful for high-throughput expression profiling of archived clinical samples...
  16. ncbi request reprint Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  17. ncbi request reprint Gene-expression signatures in oncology diagnostics
    Abhijit Mazumder
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    Pharmacogenomics 7:1167-73. 2006
    ..This article will examine some of these issues in greater detail, focusing on tissue type, platform comparison, biospecimen collection and signature validation...
  18. doi request reprint Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy
    Dmitri Talantov
    Veridex LLC, Raritan, New Jersey, USA
    J Urol 184:1521-8. 2010
    ..We combined an established nomogram and what to our knowledge are novel molecular predictors into a new prognostic model of prostate specific antigen recurrence...
  19. doi request reprint Multicenter evaluation of an investigational prostate cancer methylation assay
    Jonathan Baden
    Veridex, LLC, Raritan, New Jersey, USA
    J Urol 182:1186-93. 2009
    ..0 ng/ml. We evaluated an investigational prostate cancer methylation specific polymerase chain reaction assay that detects aberrant methylation in 3 markers (GSTP1, RARbeta2 and APC) that indicate the presence of prostate cancer...
  20. doi request reprint Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer
    Yuqiu Jiang
    Veridex, LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Clin Chem 56:1492-5. 2010
    ..There is a paucity of tumor-derived tissue available for molecular studies of CRPC patients. Circulating tumor cells (CTCs) in the blood of CRPC patients represent a possible avenue for interrogating the disease of such patients...
  21. pmc Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, LLC, Johnson and Johnson Company, San Diego, CA 9212, USA
    BMC Cancer 4:56. 2004
    ..This study was conducted to identify genetic markers and pathways that are regulated by tipifarnib in acute myeloid leukemia (AML)...
  22. doi request reprint Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:4442-8. 2008
    ..To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site...
  23. doi request reprint Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    Carey K Anders
    Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
    J Clin Oncol 26:3324-30. 2008
    ..Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined...
  24. doi request reprint The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine
    John A Foekens
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Drug Discov Today 13:481-7. 2008
    ..Here, we provide a short overview of the recent, promising developments in the field with emphasis on breast cancer...
  25. doi request reprint Subtypes of breast cancer show preferential site of relapse
    Marcel Smid
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Res 68:3108-14. 2008
    ..The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site...
  26. doi request reprint Validation and integration of gene-expression signatures in cancer
    Abhijit Mazumder
    Expert Rev Mol Diagn 8:125-8. 2008
  27. ncbi request reprint Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  28. pmc Lung metastasis genes couple breast tumor size and metastatic spread
    Andy J Minn
    Department of Radiation and Cellular Oncology, Center for Molecular Oncology, and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 104:6740-5. 2007
    ....
  29. ncbi request reprint Genes associated with breast cancer metastatic to bone
    Marcel Smid
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
    J Clin Oncol 24:2261-7. 2006
    ..The biology of tumors relapsing to bone is poorly understood. In this study, we initiated a search for genes that are implicated in tumors relapsing to bone in breast cancer...
  30. ncbi request reprint Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 24:1665-71. 2006
    ..The aim of this study was to validate this gene signature in an independent more diverse population of LNN patients from multiple institutions...
  31. ncbi request reprint A smooth response surface algorithm for constructing a gene regulatory network
    Hongquan Xu
    Department of Discovery Research Informatics, Bioinformatics, Pfizer Global Research and Development, Ann Arbor 48105, USA
    Physiol Genomics 11:11-20. 2002
    ....
  32. pmc Age-specific differences in oncogenic pathway deregulation seen in human breast tumors
    Carey K Anders
    Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina, USA
    PLoS ONE 3:e1373. 2008
    ..To define the biology driving the aggressive nature of breast cancer arising in young women...